Abstract:The Conference on Asian Trends in Prostate Cancer Hormone Therapy is an annual forum for Asian urologists now in its 5th year. The 2006 conference, held in Bali, Indonesia, was attended by 27 leading urologic oncologists from China, Indonesia, Japan, Korea, Singapore, and Taiwan and featured a packed program of presentations and discussions on a wide range of topics such as relationships among clinicians and the newly opened Asia Regional Office for Cancer Control of the International Union Against Cancer (UICC), detection rates of prostate cancer by biopsy in each of the 6 Asian countries, and favored treatment modalities for hormone-refractory prostate cancer (HRPC) in each country. The first session of the conference kicked off with a keynote lecture entitled "Activities of the UICC ARO". UICC's new office will be the nerve center for its activities in the Asia region. Along with the Asian Pacific Organization for Cancer Prevention (APOCP), UICC aims to shift the focus of attention to cancer control. As such APOCP's long-running publication the APJCP is to be re-launched as the Asian Pacific Journal of Cancer Control. Although UICC is primarily concerned with cancer, several risk factors for cancer are common also to other non-communicable diseases such as diabetes and heart disease, and an important strategy is to implement measures to control these various pathologic conditions as a whole. Apart from contributing to an Asian prostate cancer registry the UICC-ARO will provide training courses, working groups, and assistance in collecting and processing data. The keynote lecture was followed by a roundtable discussion on possible ways in which clinicians from each Asian country can work with UICC. A number of suggestions were put forth including better registration, epidemiology research, possible implementation of UICC prostate cancer guidelines, early detection and screening, and roles of diet and phytotherapy. The underlying reasons for the large but dwindling difference in incidence rates of prostate cancer in various regions of Asia should be studied while the opportunity lasts. Session 2 was devoted to 6 presentations on detection rates by biopsy in each country. Although biopsy is the gold standard for detecting prostate cancer in most areas, indications for conducting biopsy are different in each country. For example, in Indonesia doctors may use PSAD 0.15 as the cutoff level. TRUS-guided biopsy is most widely used in Asian countries. Traditional sextant biopsy is often performed, although multiple-core biopsy is commonly available and associated with better detection rates, especially in men with large prostate volume. Positive DRE, high PSA, and older age were identified as factors associated with high biopsy detection rate, although elevated PSA has limited specificity. First biopsy in men with elevated PSA had a positive detection rate of approximately 30% in all countries. Community-based screening in some countries has an overall detection rate of approximately 1%. The favorable treatment modality for HRPC was the subject of the final session. First priority for doctors in all 6 countries is to maintain serum testosterone at castration level. Many therapeutic options are available, from cytotoxic drugs to traditional herbal medicines Chemotherapeutic agents such as estramustine, docetaxel, cyclophosphamide, and mitoxantrone are often given to patients with HRPC although not all are available in every country. Prednisone and dexamethasone are used for secondary hormonal therapy. External beam radiotherapy, radioisotopic drugs such as strontium 89, and bisphosphonates are common choices to control bone pain.

Asian Society of Gynecologic Oncology International Workshop 2014

Asian Society of Gynecologic Oncology International Workshop 2018

Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)

P1119 Comparative Study of Neoadjuvant Intravenous Versus Intraarterial Chemotherapy Versus Brachytherapy Followed by Radical Surgery Versus Radical Surgery Alone in Stage IB2–IIA Bulky Cervical Cancers: a Phase III Randomized Clinical Trial in Shanghai

From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps

Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.

Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer

East Asian Gynecologic Oncology Trial Group (EAGOT): Founding History and Future Perspective

The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

Survival Outcomes of Young Patients under 40 with Breast Cancer in Asian Countries According to Subtype: an International Multicenter Cohort Study.

Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia

Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

Major clinical research advances in gynecologic cancer in 2019

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference

Progress in Diagnosis and Treatment of Gynecological Tumors in 2022

The 2nd Conference on Asian Trends in Prostate Cancer Hormone Therapy.

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3